Global Cancer Pain Therapeutics Market 2015-2019

2016-01-20
Price :
Published : Jan-2016
No. of Pages : 61

Cancer pain can be acute or chronic, depending on its stages and types. Cancer pain is caused by the tumor pressing against bones, nerves, or other organs in an individual’s body. Pain control is imperative not only for people who have advanced cancer but also for those whose condition remains stable for years. Pharmaceutical interventions such as non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and adjuvant pain medications are used to treat cancer pain.

The analysts forecast global cancer pain therapeutics market to grow at a CAGR of 9.08% during the period 2016-2020.

Covered in this report

This report covers the present scenario and the growth prospects of the global cancer pain therapeutics market for 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of cancer pain.

The market is divided into the following segments based on region:

  • Americas: The US, Canada, Mexico, and Brazil
  • EMEA: The UK, Germany, Italy, France, Spain, Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
  • APAC: Japan, China, Australia, Singapore, South Korea, and India

This report, Global Cancer Pain Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • BioDelivery Sciences
  • ProStrakan Group
  • Teva Pharmaceuticals
  • Yamaha

Other prominent vendors

  • Daiichi Sankyo
  • Eli-lilly
  • Galena Biopharma
  • Grunenthal Group
  • GW Pharmaceuticals
  • Hospira
  • Johnson & Johnson
  • Meda Pharmaceuticals
  • Orexo
  • Sanofi
  • Sorrento Therapeutics
  • WEX Pharmaceuticals

Market driver

  • Unmet medical needs
  • For a full, detailed list, view our report

Market challenge

  • Off-label drug use
  • For a full, detailed list, view our report

Market trend

  • Increase in awareness
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
Filed in: Pharmaceutical, Therapeutics
Publisher : Technavio
More Reports
Title Price Buy Now

EpiCast Report: Growth Hormone Deficiency – Epidemiology Forecast to 2026

EpiCast Report: Growth Hormone Deficiency - Epidemiology Forecast to 2026 Summary GHD is an endocrine disorder characterized by the insufficient production of GH by the pituitary gland (CGF, 2003). The ICD-10 Clinical Modification (ICD-10-CM) code for GHD is E23.0. GHD is more commonly seen in children, although it can develop during adulthood. GHD can be present from birth, in which case it is known as congenital, or it can be secondary due to brain trauma and is known as acquired. The signs and symptoms of the disease can vary. Generally, a child with GHD is born with normal size at birth, but has delayed rates of bone development and bone lengthening later on. GHD in children affects growth and development. In the 7MM, the diagnosed prevalent cases of GHD for all ages and both sexes ......
$3995

EpiCast Report: Venous Thromboembolism – Epidemiology Forecast to 2026

EpiCast Report: Venous Thromboembolism - Epidemiology Forecast to 2026 Summary Venous thromboembolism (VTE), which is composed of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a blood clot (thrombosis) of the circulatory system that leads to impeded blood flow, which can have serious consequences in the affected individual (Heit, 2015). In VTE, a DVT is a clot that occurs only in the veins; generally, they occur in the deep veins of the legs and pelvis, but may also occur in the veins of the upper body (AHA, 2017; Cohen et al., 2007; Heit, 2015). The clot may break off from its original location and travel throughout the circulatory system, and if the clot ends up in the lung, it is known as a PE (AHA, 2017). Our epidemiologists forecast an increase in the diagnosed inciden......
$3995

Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2016. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the......
$3500

Chlamydia Tests – Medical Devices Pipeline Assessment, 2017

Chlamydia Tests - Medical Devices Pipeline Assessment, 2017 Summary GlobalData's Medical Devices sector report, "Chlamydia Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Chlamydia Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Chlamydia Tests pipeline products. This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team o......
$2500

Bronchiolitis Obliterans Global Clinical Trials Review, H1, 2017

Bronchiolitis Obliterans Global Clinical Trials Review, H1, 2017 Summary GlobalData's clinical trial report, "Bronchiolitis Obliterans Global Clinical Trials Review, H1, 2017" provides an overview of Bronchiolitis Obliterans clinical trials scenario. This report provides top line data relating to the clinical trials on Bronchiolitis Obliterans. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Phar......
$2500

Cancer Anorexia-Cachexia Syndrome Global Clinical Trials Review, H1, 2017

Cancer Anorexia-Cachexia Syndrome Global Clinical Trials Review, H1, 2017 Summary GlobalData's clinical trial report, "Cancer Anorexia-Cachexia Syndrome Global Clinical Trials Review, H1, 2017" provides an overview of Cancer Anorexia-Cachexia Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Cancer Anorexia-Cachexia Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using Glob......
$2500

Bradycardia Global Clinical Trials Review, H1, 2017

Bradycardia Global Clinical Trials Review, H1, 2017 Summary GlobalData's clinical trial report, "Bradycardia Global Clinical Trials Review, H1, 2017" provides an overview of Bradycardia clinical trials scenario. This report provides top line data relating to the clinical trials on Bradycardia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials ......
$2500

Bronchitis Global Clinical Trials Review, H1, 2017

Bronchitis Global Clinical Trials Review, H1, 2017 Summary GlobalData's clinical trial report, "Bronchitis Global Clinical Trials Review, H1, 2017" provides an overview of Bronchitis clinical trials scenario. This report provides top line data relating to the clinical trials on Bronchitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are ......
$2500

Brain Cancer Global Clinical Trials Review, H1, 2017

Brain Cancer Global Clinical Trials Review, H1, 2017 Summary GlobalData's clinical trial report, "Brain Cancer Global Clinical Trials Review, H1, 2017" provides an overview of Brain Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Brain Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical tri......
$2500

Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2017

Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2017 Summary GlobalData's clinical trial report, "Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2017" provides an overview of Bronchopulmonary Dysplasia clinical trials scenario. This report provides top line data relating to the clinical trials on Bronchopulmonary Dysplasia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary databas......
$2500